| Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | Ibuprofen, Naproxen, Indomethacin | Acute kidney injury (AKI) due to reduced renal blood flow | Use with caution in patients with pre-existing kidney disease; monitor renal function, especially in elderly or dehydrated patients. | 
 | Aminoglycosides | Gentamicin, Tobramycin, Amikacin | Nephrotoxicity due to tubular cell damage, leading to acute tubular necrosis (ATN) | Monitor drug levels and renal function; limit duration of therapy and ensure adequate hydration. | 
 | Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors) & Angiotensin II Receptor Blockers (ARBs) | Lisinopril, Enalapril, Losartan, Valsartan | Can cause a decrease in glomerular filtration rate (GFR), leading to acute kidney injury | Monitor renal function and potassium levels, especially in patients with heart failure, chronic kidney disease (CKD), or volume depletion. | 
 | Contrast Agents | Iodinated contrast for CT scans | Contrast-induced nephropathy (CIN), characterized by acute kidney injury | Use the lowest effective dose; ensure adequate hydration before and after contrast administration; consider alternatives in high-risk patients. | 
 | Calcineurin Inhibitors | Ciclosporin, Tacrolimus | Chronic interstitial nephritis, leading to progressive kidney damage | Monitor drug levels and renal function regularly; adjust dose as needed to minimize toxicity. | 
 | Diuretics | Furosemide, Hydrochlorothiazide | Volume depletion leading to pre-renal azotemia; electrolyte imbalances | Monitor electrolytes and renal function; adjust dose based on patient response and avoid over-diuresis. | 
 | Amphotericin B | Conventional Amphotericin B | Nephrotoxicity due to tubular cell damage and electrolyte imbalances | Use liposomal formulations if possible; monitor renal function and electrolytes closely; ensure adequate hydration. | 
 | Chaemotherapeutic Agents | Cisplatin, Methotrexate | Acute kidney injury due to tubular toxicity; can lead to chronic kidney disease | Monitor renal function and hydration status; use protective agents like amifostine with cisplatin; dose adjustment may be required. |